Navigating Psychedelics For Clinicians and Wellness Practitioners: Australia
Everything professionals need to know about psychedelics and psychedelic integration
What is Navigating Psychedelics for Clinicians and Wellness Practitioners: Australia?
Navigating Psychedelics: For Clinicians and Wellness Practitioners - Australia is a transformative educational program for clinicians and wellness practitioners that provides an in-depth understanding of psychedelic substances, their history, therapeutic potential, and responsible use.
This course is designed as a general introduction to the field of psychedelics in an Australian context. It is designed for Clinicians, Wellness practitioners and the psychedelic curious.
This course will provide essential background knowledge for people who are interested in progressing their career in the field and wish to do the advanced clinical skills training (with Psychedelic Institute Australia) in order to work in clinical trials and other settings where psychedelics are used for therapeutic purposes.
The psychedelic landscape in Australia is undergoing a rapid transformation, marking a historic milestone in the world of therapeutic treatments. From July 2023, the Therapeutic Goods Administration (TGA) has approved the prescription of MDMA and psilocybin for specific mental health conditions, making Australia the first country to legalize the prescription of psychedelic drugs for therapeutic use.
This groundbreaking decision was founded on compassionate grounds and available scientific evidence revealing the efficacy of MDMA and psilocybin in treating treatment-resistant depression and post-traumatic stress disorder. The TGA has imposed strict regulations to ensure safe administration. Only TGA-approved psychiatrists are allowed to prescribe these drugs, and they are reserved for patients who have been diagnosed with approved conditions and have not responded to conventional treatments.
This move represents a significant stride towards advancing mental health treatments in Australia. Nonetheless, it is crucial to recognize that psychedelic therapies are still in the early stages of clinical research, and further studies are imperative to fully comprehend their safety and effectiveness. For this same reason, education around how to safely use these substances is paramount.
Excitingly, the Australian government is considering policy changes to facilitate more extensive psychedelic research and improve accessibility to psychedelic therapy.
Navigating Psychedelics: Australia includes Psychedelics Today’s original library of content from Navigating Psychedelics, plus specific content for those living in Australia who want to learn more about how to get started and more involved in the field. Our course is taught by leading experts in the field of psychedelic research and therapy - Renee Harvey M.A. Clin.Psych. & Diego Pinzon M.A.
What will I learn?
By enrolling in Navigating Psychedelics you will be educated on the most up-to-date information on psychedelics, including:
- Psychedelic history
- Evidence-based theory and current data
- Preparation, risk and safety
- Clinical applications
- Working with Challenging Experiences
- Ethical and Legal considerations
- Insights from experienced professionals already working in the field
Course Curriculum Outline:
Note: The curriculum is subject to change depending on group interests and guest presenters
Week 1 - Introduction to Psychedelics: This week acquaints students with the world of psychedelics through a historical overview, exploration of key substances, and the origins of the term "psychedelics." The course structure and learning objectives will also be outlined.
Week 2 - Psychedelic Research: Past, Present and Future: Delving from the 50s and 60s to modern times, this week reviews the evolution of psychedelic research. It will discuss current advancements and lay the groundwork for potential future research directions.
Week 3 - Preparation, risk and safety. From a harm reduction perspective, this week imparts vital knowledge for preparing safely, assessing and reducing risk when working with clients who will undergo psychedelic therapy.
Week 4 - The Psychedelic Experience: Unveiling the intricacies of altered states of consciousness, this week delves into the dimensions of psychedelic experiences. Different theoretical frameworks will be explored to help students understand and interpret these profound states.
Week 5 - Psychedelic Therapy: Week five delves into the workings of psychedelic therapy. It will explore the structure and methodologies employed within this therapeutic approach, shedding light on its unique modus operandi.
Week 6 - Working with Challenging Experiences: Addressing a significant facet of psychedelics, this week examines challenging experiences that can arise. Students will learn how to recognize, support, and navigate these moments during psychedelic journeys.
Week 7: Integration. Essential for Meaningful Growth: integration is explored this week. It provides insight into how to incorporate psychedelic insights into daily life, covering various approaches to integrate these experiences effectively.
Week 8 - Legal and Ethical Considerations: Shifting focus to legal and ethical aspects, this week discusses recent regulatory changes in Australia concerning substances like MDMA and Psilocybin. Additionally, it delves into the ethical dilemmas within the psychedelic realm.
Week 9 - Integration Projects: Concluding the course, students will present their integration projects. This final week provides an opportunity for participants to showcase how they've translated course concepts into tangible projects for real-world application.
What is the time commitment?
Nine consecutive weeks involve interactive, 1.5-hour sessions over Zoom that will educate and guide healthcare professionals on psychedelic medicine. A final project will conclude the course in Week 9.
Upon finishing the course participants will receive a Navigating Psychedelics certificate of course completion. (Note this course is for educational purposes. Psychedelics Today does not train therapists to facilitate psychedelic assisted psychotherapy.)
Space is limited!
We have kept groups small and intimate to ensure that all students are able to contribute to the live group discussions.
Renee Harvey M.A. Clin.Psych.
Renee Harvey is a highly experienced clinical psychologist who relocated from the UK to Australia to develop training in psychedelic-assisted psychotherapy (PAP). She has many years of experience as a lecturer, trainer, clinician and service developer within the mental health field. Her ideas on PAP training are featured in a recently published book chapter (Harvey, 2021) and in various talks and podcasts.
Prior to relocation, Renee was an Honorary Research Fellow and assistant guide in the Imperial College London trial researching psilocybin for treatment-resistant depression. She also facilitated the development of psychedelic interest groups and established and ran a psychedelic Integration Circle in Brighton.
Renee has worked as an assistant therapist on the psilocybin trials at St Vincent’s Hospital, Melbourne, aimed at the alleviation of depression and anxiety associated with life-threatening illnesses. She is also on the Clinical Advisory Board of Reset Mind Sciences, providing therapist training for their psychedelic research program. She also has a private practice in Melbourne with an emphasis on providing psychedelic integration.
Renee is also currently providing intensive clinical training in psychedelic-assisted psychotherapy for other research teams across Australia, as well as providing supervision to trial therapists and contributing to developing research protocols. She also provides introductory courses in collaboration with Psychedelics Today. She is also currently an Adjunct Associate Professor at the University of Western Australia.
Diego Pinzon M.A.
Originating from Colombia and now deeply ingrained in the Australian psychedelic scene, Diego brings an international perspective and deep commitment to the field of psychedelic therapy. After moving to Australia in 2008, his dedication led him to earn a Bachelor of Science in Psychology from the University of Canberra, followed by a Masters in Transpersonal Psychology from Sofia University in California.
Diego has navigated the psychedelic landscape through significant roles in the non-profit sector and the esteemed Psychae Institute. His contributions to Australia's groundbreaking psilocybin trial for end-of-life depression and anxiety at St. Vincent’s Melbourne underline his commitment to this transformative field.
Always eager to delve deeper into the world of psychedelic education, Diego was among the first in Australia to complete the 12-month training program, Vital, from Psychedelics Today. Now, he harnesses his expertise as an instructor and coordinator for the program, guiding and inspiring the next generation of psychedelic facilitators.
Beyond his professional endeavors, Diego is a passionate practitioner of martial arts, swimming, and meditation, reflecting his holistic view of health and well-being. His keen interest in Somatic and Transpersonal approaches to psychotherapy embodies his belief in a comprehensive approach to mental health.
Join Diego as he unravels the mysteries of the human mind, drawing on his extensive research experience and commitment to transformative healing practices in the realm of psychotherapy. Be part of this exciting journey into the frontiers of consciousness, guided by an expert who embodies the spirit of exploration and transformation.
Martin Williams Ph.D.
Martin Williams, PhD is a Senior Research Fellow at the Centre for Mental Health, Swinburne University, and Adjunct in Computational Neuroscience at the Turner Institute at Monash. Martin’s research background is in Medicinal Chemistry and Pharmacology at the Monash Institute of Pharmaceutical Sciences, and he is Executive Director of Psychedelic Research in Science & Medicine (PRISM) and Vice-President of Entheogenesis Australis (EGA).
Martin is a co-investigator on a number of Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne PsiloDep pilot study and 3PAP RCT of 2- vs 3-dose psilocybin-assisted therapy for depression; and several other studies of psilocybin, MDMA and other psychedelics for the treatment of a range of mental health conditions.
Martin has been an articulate advocate for psychedelic medical research and the evidence-based clinical translation of psychedelic-assisted therapies for almost twenty years. He has co-authored several academic papers providing an Australian perspective on the subject, including a recent influential Perspectives paper in Frontiers in Psychiatry, and is co-editor of an upcoming special topic issue of Frontiers, Beyond Psilocybin: Exploring the Clinical Potential of Novel and Alternative Psychedelics . He presents regularly at conferences and symposia, and is a frequent commentator on psychedelic research and governance in Australian print and broadcast media.
Petra Skeffington Ph.D.
Associate Professor Petra Skeffington is a Clinical Psychologist in Private Practice, and an academic at Murdoch University in Perth. Her research and clinical expertise centres on psychological trauma and recovery, including resilience to trauma, prevention of post-trauma pathologies, and innovative approaches to treating psychological trauma. A/Prof Skeffington was one of the first Australians to achieve MAPS certification for MDMA-Assisted Psychotherapy in early 2023, is a lead therapist on a clinical trial investigating MDMA-Assisted Psychotherapy, and is part of the therapy team on a clinical trial investigating Psilocybin-Assisted Psychotherapy.
Dr. Stephen Bright
Dr. Stephen Bright is a clinically-trained psychologist who has worked in the field for more than 20 years. He has been the chief principal investigator of multisite clinical trials and has published research on psychedelics, microdosing, psychometrics and drug policy. Currently, Stephen is principal investigator on a trial investigating MDMA for post-traumatic stress disorder (PTSD) and an associate investigator of a trial of psilocybin-assisted psychotherapy for treatment-resistant depression for which he is also the lead therapist. Stephen supervisors PhD and Masters students’ research at Edith Cowan University, where he teaches counselling skills and psychopharmacology. Dr Bright has given expert testimony to parliamentary inquest and court hearings. He was awarded Edith Cowan University’s Most Prolific Conversation Author in 2018 and 2019. In his spare time, Steve enjoys kite surfing along Perth’s beaches.
Downloadable eBooks/PDFs of our popular Trip Journal and Integration Workbooks!
Are you planning a journey in the near future or working with clients who may be planning a trip? This journal is something you don't want to forget!
This journal will also help you or your clients best prepare for their experience and aids as a wonderful tool for self-exploration.
The Navigating Psychedelics Trip Journal is the ultimate book to help one prepare, track, and begin to work with their psychedelic experiences.
In this 68 page book, you will find preparation tips and advice, journal prompts, a psychedelic trip checklist, a trip report section, and more.
Have you had a psychedelic experience and are unsure how to work with the experience?
Psychedelic experiences can be difficult, confusing, blissful, and life-changing, but knowing what to do next can be overwhelming. That is why we have designed the Navigating Psychedelics Integration Workbook to help you with your process.
This workbook can also be used with your clients as a starting point for their integration process.
We have received amazing feedback from therapists and coaches who have been using these books with clients and absolutely LOVE them!
This workbook consists of different activities such as meditation prompts, journaling exercises, and goal planning.
Frequently Asked Questions
By enrolling in this course, you are agreeing that you understand the purpose and limitations of this course.
Financial Assistance for Students
If you are a student and cannot afford this course, please email us at [email protected] FROM a university .edu.au email address. We will offer you a discount coupon for the independent learner edition.
You must email us from your school's email address to receive this discount.
Students must be enrolled in a graduate program studying psychology, social work, counseling, and etc.
On the principle of accessibility we are also offering scholarships to those currently experiencing financial hardship. Please email us.
Please note that the pricing options are in AUD and not USD.